Eli Lilly & Co. - LLY STOCK NEWS

Eli Lilly reported a 15% revenue growth in Q1 2022, amounting to $7.81 billion, driven by a 20% volume increase. Excluding COVID-19 antibody revenues, growth was 10%. The company's key products contributed significantly, with Trulicity, Verzenio, and Jardiance driving most of the growth, representing 61% of core revenue. Reported EPS was $2.10, a 41% increase, with non-GAAP EPS at $2.62, up 63%. Updated EPS guidance for 2022 is $7.30 to $7.45 reported and $8.15 to $8.30 non-GAAP.

Eli Lilly's tirzepatide has shown significant results in the SURMOUNT-1 clinical trial, achieving up to 22.5% weight loss in participants over 72 weeks. The study, which involved 2,539 participants, indicated that 63% of those on the 15 mg dose lost at least 20% of their body weight. Tirzepatide met all co-primary and key secondary endpoints, and the safety profile was comparable to existing therapies. Adverse events were mostly mild to moderate, with gastrointestinal issues being common. Ongoing studies will further evaluate its long-term effects and potential diabetes progression.

Boehringer Ingelheim and Eli Lilly have launched Hear Your Heart, an initiative aimed at empowering women, particularly Black and Latina women, who are living with heart failure. Heart disease is the leading cause of death in the U.S., affecting over six million people, with women often facing worse outcomes compared to men. The program provides tailored resources and education to help women prioritize their care, address health disparities, and optimize heart failure management. This initiative underscores the importance of equitable healthcare for this underserved population.

Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2022 financial results on April 28, 2022. Following this, the company will hold a conference call at 9 a.m. Eastern time to discuss the financial performance with investors and media. A live webcast will be available on Lilly's official website, along with a replay post-call. Lilly has a significant history of impacting global health with its innovative medicines, which help over 47 million people worldwide.

Lilly's lebrikizumab, an investigational IL-13 inhibitor, showed significant promise in treating moderate-to-severe atopic dermatitis (AD) in the ADhere trial. At 16 weeks, 70% of patients treated with lebrikizumab and topical corticosteroids (TCS) achieved EASI-75, compared to 42% with placebo. Improvements were noted in skin clearance, itch, sleep, and quality of life. Safety profiles were consistent with previous studies, with mild adverse events reported. Lilly seeks to advance lebrikizumab globally after receiving Fast Track designation from the FDA.

Eli Lilly and Company (NYSE: LLY) reported updated data from the Phase 1/2 LIBRETTO-001 trial for Retevmo® (selpercatinib) in treating RET fusion-positive non-small cell lung cancer (NSCLC). The study involved 355 patients, revealing a confirmed objective response rate of 61.1% for previously treated patients and 84.1% for treatment-naïve patients. Notably, the CNS objective response rate was 84.6%. The safety profile was consistent with prior knowledge, with common adverse effects including dry mouth and hypertension. A Phase 3 trial is underway, with results expected in 2023.

Innovent Biologics and Eli Lilly expand their strategic partnership to enhance cancer treatment options in China. Innovent will acquire sole commercialization rights for Cyramza® and Retsevmo® upon approval, and a right of first negotiation for Pirtobrutinib. Cyramza® is crucial for gastric and liver cancer, filling a significant treatment gap in China. The deal involves a total payment of US$45 million upon regulatory approvals. This agreement aims to increase Innovent's oncology portfolio to seven products, benefiting cancer patients.

On March 26, 2022, Eli Lilly released data from pivotal Phase 3 studies on OLUMIANT (baricitinib) for adults with severe alopecia areata, showing nearly 40% of patients on 4-mg achieved at least 80% scalp coverage at 52 weeks. Results indicate significant eyelash and eyebrow regrowth in those treated. The FDA granted priority review for OLUMIANT in February 2022, marking it as a potential first-in-disease treatment. Safety profiles were consistent over 52 weeks, with no new safety signals reported, reinforcing its promise as a key therapeutic option.

Eli Lilly and Company (NYSE: LLY) announced significant results from its ADvocate program, revealing that over 50% of patients with moderate-to-severe atopic dermatitis treated with the investigational drug lebrikizumab experienced a 75% reduction in disease severity (EASI-75) after 16 weeks. The treatment also provided substantial improvements in itch and skin clearance. Safety evaluations indicated a lower frequency of adverse events compared to placebo. Lilly plans to submit regulatory filings for lebrikizumab by the end of 2022.